에 대한 최신 뉴스 Liquidia (NASDAQ:LQDA) 주식

Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Corp

Baird analyst Ben Kallo maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Outperform and lowers the price target from $267 to $240.

News

Price Target

Analyst Ratings

FSLR

Baird Maintains Outperform on First Solar, Lowers Price Target to $240

APLD: -15% &#x7C; <a href="https://www.benzinga.com//node/44809868">Applied Digital shares are trading lower after the company reported a Q3 revenue miss.</a>
&nbsp;
ALGM: -14% &#x7C; <a href="https://www.benzinga.com//node/44802084">Allegro MicroSystems shares are trading lower after ON Semiconductor withdrew its acquisition proposal.</a>
&nbsp;
MTVA: 39% &#x7C; <a href="https://www.benzinga.com//node/44808973">MetaVia's Top-Line Data From 4-Week Phase 1 MAD Trial of DA-1726 Shows Compelling Weight Loss and Safety Effects With Potential GLP-1R, Waist Reduction and Tolerability</a>

Movers

Trading Ideas

ALGM

APLD

MTVA

Market-Moving News for April 15th

ST. LOUIS, April 15, 2025 /PRNewswire/ -- Peabody (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) today announced it has signed a contract to provide seven to eight million tons of coal per year to Associated Electric Cooperative Inc. (Associated) for at least the next seven years.
"This substantial agreement demonstrates the ongoing importance of Peabody's coal in providing reliable, affordable baseload electricity for years to come," said Peabody President and Chief Executive Officer Jim Grech. "American demand for electricity is growing for the first time in many years given increased power needs from data centers and artificial intelligence. We are pleased to extend our long-term relationship with Associated and look forward to supplying their fuel needs well into the future."
Under this new contract, Peabody will supply Associated's coal requirements for the New Madrid Power Plant and Thomas Hill Energy Center in Missouri from the North Antelope Rochelle Mine (NARM), located in Wyoming's Powder River Basin.&nbsp;
Peabody's NARM Mine has delivered coal to Associated generating stations for over 30 years. NARM is the largest coal mine in North America and one of the largest in the world, selling 60 million tons of coal in 2024.

Contracts

Peabody Signs Multi-Year Contract To Provide Seven To Eight Million Tons Of Coal Per Year To Associated Electric Cooperative

Management

TRVG

trivago Appoints Wolf Schmuhl As Chief Financial Officer Effective June 1

Baird analyst George Gianarikas maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Neutral and lowers the price target from $9 to $5.

FLNC

Baird Maintains Neutral on Fluence Energy, Lowers Price Target to $5

Tech

General

Parsons' Sealing Technologies Launches Two Edge Computing Nodes, GN 7100 And GN 9000

TAMPA, FLORIDA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 15, 2025 / Wellgistics Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that it has entered into an amendment to the Membership Interest Purchase Agreement with Wellgistics LLC and Wellgistics LLC's former owners to convert a significant cash payment owed by the Company into shares of the Company's common stock at the initial public offering price of $4.50 per share. Specifically, the Company has converted $1.5 million in debt that the Company owed to a seller entity controlled by Brian Norton, its Chief Executive Officer, and that the Company would have needed to pay by June 14, 2025. The $1.5 million in debt was converted into 333,333 shares of the Company's common stock.
This conversion reflects Mr. Norton's deep belief in the Company's strategic direction and his commitment to creating long-term shareholder value. Further reinforcing Mr. Norton's belief in the Company's long-term success, the 333,333 newly issued shares of the Company's common stock are subject to a 12-month lock-up agreement, whereby Mr. Norton is prohibited, except in certain limited exceptions, from selling or transferring such shares.

WGRX

CEO of Wellgistics Health Converts $1.5M of Debt to Equity at IPO Price of $4.50/Shr

Baird analyst Ben Kallo maintains Darling Ingredients (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) with a Outperform and lowers the price target from $51 to $41.

Baird Maintains Outperform on Darling Ingredients, Lowers Price Target to $41

Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) reported quarterly losses of $(1.96) per share which missed the analyst consensus estimate of $(1.38) by 42.03 percent. This is a 14.78 percent increase over losses of $(2.30) per share from the same period last year.

Earnings

Earnings Misses

ADVM

Adverum Biotechnologies Q4 EPS $(1.96) Misses $(1.38) Estimate

Benchmark analyst David Williams maintains MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) with a Buy and lowers the price target from $28 to $20.

Benchmark Maintains Buy on MaxLinear, Lowers Price Target to $20

Baird analyst Ben Kallo maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Outperform and lowers the price target from $32 to $27.

Baird Maintains Outperform on Bloom Energy, Lowers Price Target to $27

Baird analyst Ben Kallo maintains Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) with a Neutral and lowers the price target from $77 to $60.

Baird Maintains Neutral on Albemarle, Lowers Price Target to $60

Bank of Montreal And LINK Investment Management Launch New Workplace Savings Platform

Baird analyst Michael Ha downgrades Universal Health Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) from Outperform to Neutral and lowers the price target from $274 to $224.

Downgrades

Baird Downgrades Universal Health Services to Neutral, Lowers Price Target to $224

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is expected to remain within <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44794011/bitcoin-reclaims-momentum-as-100k-calls-resurface-and-tariff-relief-lifts-market-mood">a broad trading range of $73,000 to $94,000</a>, making the strategy of selling calls and puts to capture premium particularly effective, according to a recent report by 10x Research analysts.
What Happened: The analysis, which examines market dynamics amid ongoing <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44794011/bitcoin-reclaims-momentum-as-100k-calls-resurface-and-tariff-relief-lifts-market-mood">trade war uncertainties</a>, highlights a lack of clear momentum drivers and shifting investor behaviors in the cryptocurrency space.
The 10x report notes that Bitcoin ETF inflows have been tepid, totaling just $225 million year-to-date as of April, with the potential to turn negative due to market uncertainty stemming from President Donald Trump's tariff policies.
This marks the third consecutive month of <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">outflows for Bitcoin ETFs</a>, a trend initially driven by arbitrage-focused hedge funds rather than genuine demand.
Despite this, a new cohort of buyers, wallets holding between 100 and 1,000 BTC, emerged following Elon Musk's endorsement of Trump in August 2024, increasing their holdings by 700,000 BTC to 4.6 million to become the largest wallet group.
However, these buyers, likely family offices and asset managers aligned with a pro-crypto stance, have paused accumulation, leaving the market without a dominant marginal buyer.
Analysts at 10x emphasize that this lack of a clear buyer, combined with subdued on-chain data, suggests Bitcoin will not break out of its current range soon. 
"We expect Bitcoin to remain within a broad trading range, making the strategy of selling calls and puts to capture premium particularly effective," the report states, particularly as Bitcoin nears the midpoint of the $73,000 to $94,000 range. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44770031/will-a-fed-pivot-rekindle-the-bitcoin-bull-run-if-yes-expect-a-shift-in-institutional-sentiment-experts-say">Will A Fed Pivot Rekindle The Bitcoin Bull Run? If Yes, Expect A &#8216;Shift In Institutional Sentiment,&#8217; Experts Say</a>
Why It Matters: The report also highlights weak retail trading volumes and limited fiat inflows, as evidenced by muted <a href="https://www.benzinga.com/25/04/44789350/why-stablecoins-are-the-us-dollars-overlooked-advantage">stablecoin minting</a>, which further constrains Bitcoin's upside potential and indicates continued underperformance for altcoins.
The market's recent rally has been driven by long-term holders focused on diversification rather than speculation, with a notable slowdown in new network addresses compared to previous cycles. 
This buy-and-hold strategy, distinct from the transactional activity of past bull runs, aligns with monthly cycle indicators like the stochastic oscillator, which signal a late-cycle phase rather than a new bull run. 
Despite short-term technical improvements, such as funding and basis rates ticking above the 10% hurdle rate, historically a 77% predictor of price increases three to six months later, the broader market structure remains weak.
The 10x analysts advocate for a sophisticated approach in this environment, noting, "In an uncertain environment… selling puts (and calls) allows traders to benefit from range-bound conditions." 
With Bitcoin's support near $73,000 offering a risk-reward setup of 10% downside versus 20% upside, this strategy leverages option-implied volatility for attractive yields, contrasting with the near-zero premiums in basis trades. 
The report further states that Bitcoin's market now demands a finance-oriented skill set, with traders needing to shift between high-yield income strategies, directional positioning, and capital preservation.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44763111/bitcoin-stablecoins-will-gain-from-trade-war-experts-say-the-map-is-being-redrawn">Bitcoin, Stablecoins Will Gain From Trade War, Experts Say: &#8216;The Map Is Being Redrawn&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin To Stay Range-Bound, But Options Trading Can Yield A Profit: 10x Research

Needham analyst Chris Pierce initiates coverage on Aurora Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) with a Buy rating and announces Price Target of $10.

Initiation

Needham Initiates Coverage On Aurora Innovation with Buy Rating, Announces Price Target of $10

NCNO

ZION

Zions To Deploy nCino's Technology Platform For The Digital Transformation Of Loan Origination Process

The number of Canadian tourists visiting the U.S. has taken a significant hit, potentially resulting in a $6 billion economic loss for the year, as per reports.
What Happened: The number of Canadians traveling to the U.S. has seen a notable decline. According to Statistics Canada, road trips—which make up the bulk of Canadian visits—dropped by 32% in March compared to the same month in 2024. Air travel also fell, with a 13.5% decrease reported.
The U.S. Travel Association (USTA) had earlier cautioned that even a 10% drop in Canadian tourism could lead to a $2.1 billion loss and put 140,000 jobs in jeopardy in the hospitality and associated sectors. If the decline of over 30% in Canadian visitors persists, it could result in over $6 billion in losses to the U.S. economy in 2025, <a href="https://www.forbes.com/sites/suzannerowankelleher/2025/04/14/canadian-travel-usa-boycott-escalates/">Forbes </a>reported.
This downturn marks&nbsp;the third straight month of&nbsp;significant declines in Canadian car travel to the U.S., following a 23% year-on-year&nbsp;decline in car travel and&nbsp;a 2.4% reduction in air&nbsp;travel in February. This trend started&nbsp;after President Donald Trump announced&nbsp;tariffs and referred to Canada as &#8220;the 51st state&#8221;.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44800348/bitcoin-ethereum-xrp-dogecoin-go-sideways-but-this-trader-says-you-shouldnt-long-one-of-them" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Go Sideways But This Trader Says You &#8216;Shouldn&#8217;t Long&#8217; One Of Them &#8211; Benzinga</a>
Why It Matters: The decline in Canadian tourism <a href="https://www.benzinga.com/25/04/44592941/canadian-tourism-decline-poses-risk-to-us-airlines-hotels-and-theme-parks-details">was anticipated</a> to have a significant impact on U.S. airlines, hotels, and theme parks. Goldman Sachs analyst Lizzie Dove had warned that a 10% decline could result in 2 million fewer visits and&nbsp;$2.1 billion in lost spending&nbsp;to the U.S.
As a result of this, United Airlines&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) and Delta&nbsp;Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) which have significant partnerships with Air Canada and WestJet, respectively, are cutting down on Canada-U.S. flights while also reducing capacity in this route, as per Visual Approach Analytics.
Moreover, the &#8216;<a href="https://www.benzinga.com/personal-finance/25/04/44766548/us-brands-poised-to-lose-billions-of-dollars-in-sales-as-buy-canadian-movement-grows">Buy Canadian</a>&#8216; movement, which started in response to President Trump&#8217;s tariff threats, has been gaining momentum since early 2025. This movement, which encourages Canadians to buy from domestic brands rather than American brands, has begun to impact many U.S. retailers. 
According to Reuters, Canada imported $350 billion worth of U.S.-made goods in 2024, making it the United States&#8217; top trading partner. If the boycotts persist, brands risk losing billions of dollars in sales this year.
The shares of United Airlines plunged more than 11% over the past month, while Delta Air Lines stock lost nearly 24% over the last six months, according to data from <a href="http://pro.benzinga.com">Benzinga Pro.</a>
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/44780394/andrew-yang-wonders-if-something-goes-down-10-and-then-up-10-are-you-back-where-you-started" target="_blank" rel="noreferrer noopener">Andrew Yang Wonders, &#8216;If Something Goes Down 10% And Then Up 10%, Are You Back Where You Started?&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Canadian Travel To US Nosedives: Road Trips Down 32%, Air Travel Slips 13.5% — Report Warns Of Over $6 Billion In Economic Losses

WIIM

NFLX

Netflix shares are trading higher after a Wall Street Journal report said the company aims to double its revenue by 2030.

Baird analyst Michael Ha downgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Outperform to Neutral and lowers the price target from $153 to $137.

Comments

Liquidia

뉴스

에 대한 최신 뉴스 Liquidia (NASDAQ:LQDA) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌